[1]
Opara JA,Brola W,Wylegala AA,Wylegala E, Uhthoff`s phenomenon 125 years later - what do we know today? Journal of medicine and life. 2016 Jan-Mar;
[PubMed PMID: 27974923]
[3]
Ontaneda D,Rae-Grant AD, Management of acute exacerbations in multiple sclerosis. Annals of Indian Academy of Neurology. 2009 Oct;
[PubMed PMID: 20182574]
[5]
Smith KJ,McDonald WI, The pathophysiology of multiple sclerosis: the mechanisms underlying the production of symptoms and the natural history of the disease. Philosophical transactions of the Royal Society of London. Series B, Biological sciences. 1999 Oct 29;
[PubMed PMID: 10603618]
[7]
Park K,Tanaka K,Tanaka M, Uhthoff's phenomenon in multiple sclerosis and neuromyelitis optica. European neurology. 2014;
[PubMed PMID: 25195501]
[8]
Guthrie TC,Nelson DA, Influence of temperature changes on multiple sclerosis: critical review of mechanisms and research potential. Journal of the neurological sciences. 1995 Mar;
[PubMed PMID: 7751837]
[10]
Fraser CL,Davagnanam I,Radon M,Plant GT, The time course and phenotype of Uhthoff phenomenon following optic neuritis. Multiple sclerosis (Houndmills, Basingstoke, England). 2012 Jul
[PubMed PMID: 22146611]
[11]
Humm AM,Beer S,Kool J,Magistris MR,Kesselring J,Rösler KM, Quantification of Uhthoff's phenomenon in multiple sclerosis: a magnetic stimulation study. Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology. 2004 Nov
[PubMed PMID: 15465437]
[12]
Frohman TC,Davis SL,Frohman EM, Modeling the mechanisms of Uhthoff's phenomenon in MS patients with internuclear ophthalmoparesis. Annals of the New York Academy of Sciences. 2011 Sep
[PubMed PMID: 21951010]
[13]
Giuliodori MJ,DiCarlo SE, Myelinated vs. unmyelinated nerve conduction: a novel way of understanding the mechanisms. Advances in physiology education. 2004 Dec;
[PubMed PMID: 15149966]
Level 3 (low-level) evidence
[14]
Berdjis H,Schnaudigel OE, Uhthoff's phenomenon in the low-frequency flash-evoked cortical potential. Developments in ophthalmology. 1984;
[PubMed PMID: 6526103]
[15]
Howells J,Czesnik D,Trevillion L,Burke D, Excitability and the safety margin in human axons during hyperthermia. The Journal of physiology. 2013 Jun 15;
[PubMed PMID: 23613528]
[16]
Frohman TC,Davis SL,Beh S,Greenberg BM,Remington G,Frohman EM, Uhthoff's phenomena in MS--clinical features and pathophysiology. Nature reviews. Neurology. 2013 Sep
[PubMed PMID: 23732530]
[17]
Wingerchuk DM,Rodriguez M, Premenstrual multiple sclerosis pseudoexacerbations: Role of body temperature and prevention with aspirin. Archives of neurology. 2006 Jul;
[PubMed PMID: 16831971]
[18]
Fitzgerald KC,Cassard LA,Fox SR,Probasco JC,Cassard SD,Mowry EM, The prevalence and utility of screening for urinary tract infection at the time of presumed multiple sclerosis relapse. Multiple sclerosis and related disorders. 2019 Oct;
[PubMed PMID: 31344604]
[19]
Alfredsson L,Olsson T, Lifestyle and Environmental Factors in Multiple Sclerosis. Cold Spring Harbor perspectives in medicine. 2019 Apr 1;
[PubMed PMID: 29735578]
Level 3 (low-level) evidence
[20]
Jakimovski D,Guan Y,Ramanathan M,Weinstock-Guttman B,Zivadinov R, Lifestyle-based modifiable risk factors in multiple sclerosis: review of experimental and clinical findings. Neurodegenerative disease management. 2019 Jun;
[PubMed PMID: 31116081]
[21]
Olsson T,Barcellos LF,Alfredsson L, Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nature reviews. Neurology. 2017 Jan;
[PubMed PMID: 27934854]
[22]
van Diemen HA,van Dongen MM,Dammers JW,Polman CH, Increased visual impairment after exercise (Uhthoff's phenomenon) in multiple sclerosis: therapeutic possibilities. European neurology. 1992
[PubMed PMID: 1324180]
[23]
Espejo C,Montalban X, Dalfampridine in multiple sclerosis: from symptomatic treatment to immunomodulation. Clinical immunology (Orlando, Fla.). 2012 Jan;
[PubMed PMID: 21742559]
[24]
Goodman AD,Brown TR,Schapiro RT,Klingler M,Cohen R,Blight AR, A pooled analysis of two phase 3 clinical trials of dalfampridine in patients with multiple sclerosis. International journal of MS care. 2014 Fall;
[PubMed PMID: 25337058]
Level 1 (high-level) evidence
[25]
Haupert CL,Newman NJ, Prolonged Uhthoff phenomenon in sarcoidosis. American journal of ophthalmology. 1997 Oct;
[PubMed PMID: 9323955]
[26]
Papandony M,Wesselingh R,Stark R, Uhthoff phenomenon in osmotic demyelination syndrome. Internal medicine journal. 2014 Nov;
[PubMed PMID: 25367730]